{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ADMET", "Alzheimer\u2019s disease", "Lipinski\u2019s rule", "Parkinson\u2019s disease", "bioinformatics", "drug-likeness", "in silico", "karanjin", "molecular dynamics"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35566187", "DateCompleted": {"Year": "2022", "Month": "05", "Day": "17"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "29"}], "Language": ["eng"], "ELocationID": ["2834", "10.3390/molecules27092834"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "9", "PubDate": {"Year": "2022", "Month": "Apr", "Day": "29"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy.", "Abstract": {"AbstractText": ["Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders that have emerged as among the serious health problems of the 21st century. The medications currently available to treat AD and PD have limited efficacy and are associated with side effects. Natural products are one of the most vital and conservative sources of medicines for treating neurological problems. Karanjin is a furanoflavonoid, isolated mainly from <i>Pongamia pinnata</i> with several medicinal plants, and has been reported for numerous health benefits. However, the effect of karanjin on AD and PD has not yet been systematically investigated. To evaluate the neuroprotective effect of karanjin, extensive in silico studies starting with molecular docking against five putative targets for AD and four targets for PD were conducted. The findings were compared with three standard drugs using Auto Dock 4.1 and Molegro Virtual Docker software. Additionally, the physiochemical properties (Lipinski rule of five), drug-likeness and parameters including absorption, distribution, metabolism, elimination and toxicity (ADMET) profiles of karanjin were also studied. The molecular dynamics (MD) simulations were performed with two selective karanjin docking complexes to analyze the dynamic behaviors and binding free energy at 100 ns time scale. In addition, frontier molecular orbitals (FMOs) and density-functional theory (DFT) were also investigated from computational quantum mechanism perspectives using the Avogadro-ORCA 1.2.0 platform. Karanjin complies with all five of Lipinski's drug-likeness rules with suitable ADMET profiles for therapeutic use. The docking scores (kcal/mol) showed comparatively higher potency against AD and PD associated targets than currently used standard drugs. Overall, the potential binding affinity from molecular docking, static thermodynamics feature from MD-simulation and other multiparametric drug-ability profiles suggest that karanjin could be considered as a suitable therapeutic lead for AD and PD treatment. Furthermore, the present results were strongly correlated with the earlier study on karanjin in an Alzheimer's animal model. However, necessary in vivo studies, clinical trials, bioavailability, permeability and safe dose administration, etc. must be required to use karanjin as a potential drug against AD and PD treatment, where the in silico results are more helpful to accelerate the drug development."]}, "AuthorList": [{"Identifier": ["0000-0001-9644-6688"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Malaysia."}], "LastName": "Gnanaraj", "ForeName": "Charles", "Initials": "C"}, {"Identifier": ["0000-0002-3022-6137"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Malaysia."}], "LastName": "Sekar", "ForeName": "Mahendran", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong 08100, Malaysia."}], "LastName": "Fuloria", "ForeName": "Shivkanya", "Initials": "S"}, {"Identifier": ["0000-0001-5089-8304"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Microbiology and NCDs, ICMR-Regional Medical Research Centre, Bhubaneswar 751023, India."}], "LastName": "Swain", "ForeName": "Shasank S", "Initials": "SS"}, {"Identifier": ["0000-0001-6470-3651"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Monash University Malaysia, Bandar Sunway 47500, Malaysia."}], "LastName": "Gan", "ForeName": "Siew Hua", "Initials": "SH"}, {"Identifier": ["0000-0002-7981-4562"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia."}], "LastName": "Chidambaram", "ForeName": "Kumarappan", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Malaysia."}], "LastName": "Rani", "ForeName": "Nur Najihah Izzati Mat", "Initials": "NNIM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Malaysia."}], "LastName": "Balan", "ForeName": "Tavamani", "Initials": "T"}, {"Identifier": ["0000-0003-4454-9612"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biological Sciences, Faculty of Science and Technology, Quest International University Perak, Jalan Raja Permaisuri Bainun, Ipoh 30250, Malaysia."}], "LastName": "Stephenie", "ForeName": "Sarah", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Malaysia."}], "LastName": "Lum", "ForeName": "Pei Teng", "Initials": "PT"}, {"Identifier": ["0000-0003-3514-7654"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, India."}], "LastName": "Jeyabalan", "ForeName": "Srikanth", "Initials": "S"}, {"Identifier": ["0000-0002-1871-8585"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia."}], "LastName": "Begum", "ForeName": "M Yasmin", "Initials": "MY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Siddaganga Institute of Technology, Tumakuru 572103, India."}], "LastName": "Chandramohan", "ForeName": "Vivek", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India."}], "LastName": "Thangavelu", "ForeName": "Lakshmi", "Initials": "L"}, {"Identifier": ["0000-0002-9629-9494"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jalan SP 2, Bandar Saujana Putra, Jenjarom 42610, Malaysia."}], "LastName": "Subramaniyan", "ForeName": "Vetriselvan", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong 08100, Malaysia."}, {"Identifier": [], "Affiliation": "Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India."}], "LastName": "Fuloria", "ForeName": "Neeraj Kumar", "Initials": "NK"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Benzopyrans"}, {"RegistryNumber": "WV7IM0I02M", "NameOfSubstance": "karanjin"}], "MeshHeadingList": [{"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Benzopyrans"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Parkinson Disease"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ali M., Muhammad S., Shah M.R., Khan A., Rashid U., Farooq U., Ullah F., Sadiq A., Ayaz M., Ali M. Neurologically potent molecules from Crataegus oxyacantha; isolation, anticholinesterase inhibition, and molecular docking. Front. Pharmacol. 2017;8:327. doi: 10.3389/fphar.2017.00327.", "ArticleIdList": ["10.3389/fphar.2017.00327", "PMC5461367", "28638340"]}, {"Citation": "Ayaz M., Sadiq A., Junaid M., Ullah F., Subhan F., Ahmed J. Neuroprotective and anti-aging potentials of essential oils from aromatic and medicinal plants. Front. Aging Neurosci. 2017;9:168. doi: 10.3389/fnagi.2017.00168.", "ArticleIdList": ["10.3389/fnagi.2017.00168", "PMC5447774", "28611658"]}, {"Citation": "Patterson C. The State of the Art of Dementia Research: New Frontiers. Alzheimer\u2019s Disease International Edition; London, UK: 2018. World alzheimer report 2018; p. 148."}, {"Citation": "WHO  Dementia.  [(accessed on 15 February 2021)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/dementia."}, {"Citation": "ADFM  Alzheimer\u2019s Disease.  [(accessed on 15 February 2021)].  Available online:  https://adfm.org.my/"}, {"Citation": "Ayaz M., Junaid M., Ullah F., Subhan F., Sadiq A., Ali G., Ovais M., Shahid M., Ahmad A., Wadood A. Anti-Alzheimer\u2019s studies on \u03b2-sitosterol isolated from Polygonum hydropiper L. Front. Pharmacol. 2017;8:697. doi: 10.3389/fphar.2017.00697.", "ArticleIdList": ["10.3389/fphar.2017.00697", "PMC5635809", "29056913"]}, {"Citation": "Khalil A.T., Ayaz M., Ovais M., Wadood A., Ali M., Shinwari Z.K., Maaza M. In vitro cholinesterase enzymes inhibitory potential and in silico molecular docking studies of biogenic metal oxides nanoparticles. Inorg. Nano-Met. Chem. 2018;48:441\u2013448. doi: 10.1080/24701556.2019.1569686.", "ArticleIdList": ["10.1080/24701556.2019.1569686"]}, {"Citation": "Ovais M., Ayaz M., Khalil A.T., Shah S.A., Jan M.S., Raza A., Shahid M., Shinwari Z.K. HPLC-DAD finger printing, antioxidant, cholinesterase, and \u03b1-glucosidase inhibitory potentials of a novel plant Olax nana. BMC Complement. Altern. Med. 2018;18:1. doi: 10.1186/s12906-017-2057-9.", "ArticleIdList": ["10.1186/s12906-017-2057-9", "PMC5751879", "29295712"]}, {"Citation": "Ayaz M., Ullah F., Sadiq A., Kim M.O., Ali T. Natural products-based drugs: Potential therapeutics against Alzheimer\u2019s disease and other neurological disorders. Front. Pharmacol. 2019;10:1417. doi: 10.3389/fphar.2019.01417.", "ArticleIdList": ["10.3389/fphar.2019.01417", "PMC6889855", "31849668"]}, {"Citation": "Ovais M., Zia N., Ahmad I., Khalil A.T., Raza A., Ayaz M., Sadiq A., Ullah F., Shinwari Z.K. Phyto-therapeutic and nanomedicinal approaches to cure alzheimer\u2019s disease: Present status and future opportunities. Front. Aging Neurosci. 2018;10:284. doi: 10.3389/fnagi.2018.00284.", "ArticleIdList": ["10.3389/fnagi.2018.00284", "PMC6205985", "30405389"]}, {"Citation": "Rocca W.A. The burden of Parkinson\u2019s disease: A worldwide perspective. Lancet Neurol. 2018;17:928\u2013929. doi: 10.1016/S1474-4422(18)30355-7.", "ArticleIdList": ["10.1016/S1474-4422(18)30355-7", "30287052"]}, {"Citation": "Klemann C.J., Martens G.J., Sharma M., Martens M., Isacson O., Gasser T., Visser J., Poelmans G. Integrated molecular landscape of Parkinson\u2019s disease. NPJ Parkinsons Dis. 2017;3:14. doi: 10.1038/s41531-017-0015-3.", "ArticleIdList": ["10.1038/s41531-017-0015-3", "PMC5460267", "28649614"]}, {"Citation": "Twelves D., Perkins K.S., Counsell C. Systematic review of incidence studies of Parkinson\u2019s disease. Mov. Disord. 2003;18:19\u201331. doi: 10.1002/mds.10305.", "ArticleIdList": ["10.1002/mds.10305", "12518297"]}, {"Citation": "Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson\u2019s disease: A systematic review and meta-analysis. Mov. Disord. 2014;29:1583\u20131590. doi: 10.1002/mds.25945.", "ArticleIdList": ["10.1002/mds.25945", "24976103"]}, {"Citation": "Dorsey E.R., Constantinescu R., Thompson J., Biglan K., Holloway R., Kieburtz K., Marshall F., Ravina B., Schifitto G., Siderowf A. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384\u2013386. doi: 10.1212/01.wnl.0000247740.47667.03.", "ArticleIdList": ["10.1212/01.wnl.0000247740.47667.03", "17082464"]}, {"Citation": "Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: Filling the bench-to-bedside gap. Lancet Neurol. 2010;9:1106\u20131117. doi: 10.1016/S1474-4422(10)70218-0.", "ArticleIdList": ["10.1016/S1474-4422(10)70218-0", "20880751"]}, {"Citation": "Diaz N.L., Waters C.H. Current strategies in the treatment of Parkinson\u2019s disease and a personalized approach to management. Expert Rev. Neurother. 2009;9:1781\u20131789. doi: 10.1586/ern.09.117.", "ArticleIdList": ["10.1586/ern.09.117", "19951137"]}, {"Citation": "Muller T., Hefter H., Hueber R., Jost W.H., Leenders K.L., Odin P., Schwarz J. Is levodopa toxic? J. Neurol. 2004;251:44\u201346. doi: 10.1007/s00415-004-1610-x.", "ArticleIdList": ["10.1007/s00415-004-1610-x", "15675725"]}, {"Citation": "Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. 2002;109:411\u2013420. doi: 10.1007/s007020200033.", "ArticleIdList": ["10.1007/s007020200033", "11956961"]}, {"Citation": "Cummings J., Lee G., Ritter A., Sabbagh M., Zhong K. Alzheimer\u2019s disease drug development pipeline: 2020. Alzheimer\u2019s Dement. 2020;6:e12050. doi: 10.1002/trc2.12050.", "ArticleIdList": ["10.1002/trc2.12050", "PMC7364858", "32695874"]}, {"Citation": "McFarthing K., Buff S., Rafaloff G., Dominey T., Wyse R.K., Stott S.R. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2020. J. Parkinson\u2019s Dis. 2020;10:757\u2013774. doi: 10.3233/JPD-202128.", "ArticleIdList": ["10.3233/JPD-202128", "PMC7458531", "32741777"]}, {"Citation": "Bui T.T., Nguyen T.H. Natural product for the treatment of Alzheimer\u2019s disease. J. Basic Clin. Physiol. Pharmacol. 2017;28:413\u2013423. doi: 10.1515/jbcpp-2016-0147.", "ArticleIdList": ["10.1515/jbcpp-2016-0147", "28708573"]}, {"Citation": "Rahman M., Bajgai J., Fadriquela A., Sharma S., Trinh T.T., Akter R., Jeong Y.J., Goh S.H., Kim C.-S., Lee K.-J. Therapeutic potential of natural products in treating neurodegenerative disorders and their future prospects and challenges. Molecules. 2021;26:5327. doi: 10.3390/molecules26175327.", "ArticleIdList": ["10.3390/molecules26175327", "PMC8433718", "34500759"]}, {"Citation": "Maher P. The potential of flavonoids for the treatment of neurodegenerative diseases. Int. J. Mol. Sci. 2019;20:3056. doi: 10.3390/ijms20123056.", "ArticleIdList": ["10.3390/ijms20123056", "PMC6627573", "31234550"]}, {"Citation": "Noor A.A.M., Othman S.N.N., Lum P.T., Mani S., Shaikh M.F., Sekar M. Molecules of interest\u2013Karanjin\u2013A review. Pharmacogn. J. 2020;12"}, {"Citation": "Saini P., Lakshmayya L., Bisht V.S. Anti-Alzheimer activity of isolated karanjin from Pongamia pinnata (L.) pierre and embelin from Embelia ribes Burm.f. Ayu. 2017;38:76.", "ArticleIdList": ["PMC5954258", "29861598"]}, {"Citation": "Kim G.H., Kim J.E., Rhie S.J., Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 2015;24:325. doi: 10.5607/en.2015.24.4.325.", "ArticleIdList": ["10.5607/en.2015.24.4.325", "PMC4688332", "26713080"]}, {"Citation": "Schyman P., Liu R., Desai V., Wallqvist A. vNN web server for ADMET predictions. Front. Pharmacol. 2017;8:889. doi: 10.3389/fphar.2017.00889.", "ArticleIdList": ["10.3389/fphar.2017.00889", "PMC5722789", "29255418"]}, {"Citation": "Martell R.E., Brooks D.G., Wang Y., Wilcoxen K. Discovery of novel drugs for promising targets. Clin. Ther. 2013;35:1271\u20131281. doi: 10.1016/j.clinthera.2013.08.005.", "ArticleIdList": ["10.1016/j.clinthera.2013.08.005", "24054704"]}, {"Citation": "Pinzi L., Rastelli G. Molecular docking: Shifting paradigms in drug discovery. Int. J. Mol. Sci. 2019;20:4331. doi: 10.3390/ijms20184331.", "ArticleIdList": ["10.3390/ijms20184331", "PMC6769923", "31487867"]}, {"Citation": "Swain S.S., Paidesetty S.K., Dehury B., Das M., Vedithi S.C., Padhy R.N. Computer-aided synthesis of dapsone-phytochemical conjugates against dapsone-resistant Mycobacterium leprae. Sci. Rep. 2020;10:6839. doi: 10.1038/s41598-020-63913-9.", "ArticleIdList": ["10.1038/s41598-020-63913-9", "PMC7176699", "32322091"]}, {"Citation": "Heifetz A., Southey M., Morao I., Townsend-Nicholson A., Bodkin M.J. Computational Methods for GPCR Drug Discovery. Springer; Cham, Switzerland: 2018. Computational methods used in hit-to-lead and lead optimization stages of structure-based drug discovery; pp. 375\u2013394.", "ArticleIdList": ["29188574"]}, {"Citation": "Cruz-Vicente P., Passarinha L.A., Silvestre S., Gallardo E. Recent developments in new therapeutic agents against alzheimer and parkinson diseases: In silico approaches. Molecules. 2021;26:2193. doi: 10.3390/molecules26082193.", "ArticleIdList": ["10.3390/molecules26082193", "PMC8069930", "33920326"]}, {"Citation": "Amin M.L. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 2013;7:27\u201334. doi: 10.4137/DTI.S12519.", "ArticleIdList": ["10.4137/DTI.S12519", "PMC3762612", "24023511"]}, {"Citation": "Chang R., Yee K.-L., Sumbria R.K. Tumor necrosis factor \u03b1 inhibition for Alzheimer\u2019s disease. J. Cent. Nerv. Syst. Dis. 2017;9:1179573517709278. doi: 10.1177/1179573517709278.", "ArticleIdList": ["10.1177/1179573517709278", "PMC5436834", "28579870"]}, {"Citation": "Cheng X., Yang L., He P., Li R., Shen Y. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer\u2019s disease and non-demented patients. J. Alzheimer\u2019s Dis. 2010;19:621\u2013630. doi: 10.3233/JAD-2010-1253.", "ArticleIdList": ["10.3233/JAD-2010-1253", "PMC3746510", "20110607"]}, {"Citation": "Syaifie P.H., Hemasita A.W., Nugroho D.W., Mardliyati E., Anshori I. In silico investigation of propolis compounds as potential neuroprotective agent. Biointerface Res. Appl. Chem. 2022;12:8285\u20138306. doi: 10.33263/BRIAC126.82858306.", "ArticleIdList": ["10.33263/BRIAC126.82858306"]}, {"Citation": "K\u00f6lsch H., Jessen F., Freymann N., Kreis M., Hentschel F., Maier W., Heun R. ACE I/D polymorphism is a risk factor of Alzheimer\u2019s disease but not of vascular dementia. Neurosci. Lett. 2005;377:37\u201339. doi: 10.1016/j.neulet.2004.11.062.", "ArticleIdList": ["10.1016/j.neulet.2004.11.062", "15722183"]}, {"Citation": "Monastero R., Caldarella R., Mannino M., Cefalu A.B., Lopez G., Noto D., Camarda C., Camarda L.K., Notarbartolo A., Averna M.R. Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer\u2019s disease. Neurosci. Lett. 2002;335:147\u2013149. doi: 10.1016/S0304-3940(02)01182-5.", "ArticleIdList": ["10.1016/S0304-3940(02)01182-5", "12459519"]}, {"Citation": "Goh N.-Y., Razif M.F.M., Yap Y.H.-Y., Ng C.L., Fung S.-Y. In silico analysis and characterization of medicinal mushroom cystathionine-synthase as an angiotensin converting enzyme (ACE) inhibitory protein. Comput. Biol. Chem. 2021:107620. doi: 10.1016/j.compbiolchem.2021.107620.", "ArticleIdList": ["10.1016/j.compbiolchem.2021.107620", "34971900"]}, {"Citation": "Citron M. Emerging Alzheimer\u2019s disease therapies: Inhibition of \u03b2-secretase. Neurobiol. Aging. 2002;23:1017\u20131022. doi: 10.1016/S0197-4580(02)00122-7.", "ArticleIdList": ["10.1016/S0197-4580(02)00122-7", "12470797"]}, {"Citation": "Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer\u2019s disease. J. Neurochem. 2008;104:1433\u20131439. doi: 10.1111/j.1471-4159.2007.05194.x.", "ArticleIdList": ["10.1111/j.1471-4159.2007.05194.x", "PMC3073119", "18088381"]}, {"Citation": "Tran T.-S., Tran T.-D., Mai T.-T., Nguyen N.-L., Thai K.-M., Le M.-T. Synthesis, In silico and In vitro Evaluation of Some Flavone Derivatives for Acetylcholinesterase and BACE-1 Inhibitory Activity. Molecules. 2020;25:4064. doi: 10.3390/molecules25184064.", "ArticleIdList": ["10.3390/molecules25184064", "PMC7570966", "32899576"]}, {"Citation": "Subramanian G., Poda G. In silico ligand-based modeling of hBACE-1 inhibitors. Chem. Biol. Drug Des. 2018;91:817\u2013827. doi: 10.1111/cbdd.13147.", "ArticleIdList": ["10.1111/cbdd.13147", "29139199"]}, {"Citation": "Coimbra J.R., Baptista S.J., Dinis T.C., Silva M., Moreira P.I., Santos A.E., Salvador J.A. Combining virtual screening protocol and in vitro evaluation towards the discovery of BACE1 inhibitors. Biomolecules. 2020;10:535. doi: 10.3390/biom10040535.", "ArticleIdList": ["10.3390/biom10040535", "PMC7226079", "32244832"]}, {"Citation": "Shukla R., Munjal N.S., Singh T.R. Identification of novel small molecules against GSK3\u03b2 for Alzheimer\u2019s disease using chemoinformatics approach. J. Mol. Graph. Modell. 2019;91:91\u2013104. doi: 10.1016/j.jmgm.2019.06.008.", "ArticleIdList": ["10.1016/j.jmgm.2019.06.008", "31202091"]}, {"Citation": "Joshi P., Gupta M., Vishwakarma R.A., Kumar A., Bharate S.B. (Z)-2-(3-Chlorobenzylidene)-3,4-dihydro-N-(2-methoxyethyl)-3-oxo-2H-benzo[b][1,4]oxazine-6-carboxamide as GSK-3\u03b2 inhibitor: Identification by virtual screening and its validation in enzyme-and cell-based assay. Chem. Biol. Drug Des. 2017;89:964\u2013971. doi: 10.1111/cbdd.12913.", "ArticleIdList": ["10.1111/cbdd.12913", "27896926"]}, {"Citation": "He Q., Han C., Li G., Guo H., Wang Y., Hu Y., Lin Z., Wang Y. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation. Comput. Biol. Chem. 2020;88:107328. doi: 10.1016/j.compbiolchem.2020.107328.", "ArticleIdList": ["10.1016/j.compbiolchem.2020.107328", "32688011"]}, {"Citation": "Ranjan A., Chauhan A., Jindal T. In silico and in vitro evaluation of human acetylcholinesterase inhibition by organophosphates. Environ. Toxicol. Pharmacol. 2018;57:131\u2013140. doi: 10.1016/j.etap.2017.12.014.", "ArticleIdList": ["10.1016/j.etap.2017.12.014", "29272792"]}, {"Citation": "Castro-Silva E., Bello M., Hern\u00e1ndez-Rodr\u00edguez M., Correa-Basurto J., Murillo-Alvarez J., Rosales-Hernandez M., Mu\u00f1oz-Ochoa M. In vitro and in silico evaluation of fucosterol from Sargassum horridum as potential human acetylcholinesterase inhibitor. J. Biomol. Struct. Dyn. 2018;37:3259\u20133268. doi: 10.1080/07391102.2018.1505551.", "ArticleIdList": ["10.1080/07391102.2018.1505551", "30088792"]}, {"Citation": "Kumar B., Kumar V., Prashar V., Saini S., Dwivedi A.R., Bajaj B., Mehta D., Parkash J., Kumar V. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase. Eur. J. Med. Chem. 2019;177:221\u2013234. doi: 10.1016/j.ejmech.2019.05.039.", "ArticleIdList": ["10.1016/j.ejmech.2019.05.039", "31151057"]}, {"Citation": "Morelli M., Simola N., Wardas J. The Adenosinergic System: A Non-Dopaminergic Target in Parkinson\u2019s Disease. Volume 10 Springer; Cham, Swizterland: 2015."}, {"Citation": "Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology. 2003;61:S32\u2013S38. doi: 10.1212/01.WNL.0000095209.59347.79.", "ArticleIdList": ["10.1212/01.WNL.0000095209.59347.79", "14663007"]}, {"Citation": "Chartier-Harlin M.-C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M. \u03b1-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. The Lancet. 2004;364:1167\u20131169. doi: 10.1016/S0140-6736(04)17103-1.", "ArticleIdList": ["10.1016/S0140-6736(04)17103-1", "15451224"]}, {"Citation": "Ibanez P., Bonnet A., Debarges B., Lohmann E., Tison F., Agid Y., D\u00fcrr A., Brice A., Pollak P., Group F.P.s.D.G.S. Causal relation between \u03b1-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. The Lancet. 2004;364:1169\u20131171. doi: 10.1016/S0140-6736(04)17104-3.", "ArticleIdList": ["10.1016/S0140-6736(04)17104-3", "15451225"]}, {"Citation": "Elmer L.W., Bertoni J.M. The increasing role of monoamine oxidase type B inhibitors in Parkinson\u2019s disease therapy. Expert Opin. Pharmacother. 2008;9:2759\u20132772. doi: 10.1517/14656566.9.16.2759.", "ArticleIdList": ["10.1517/14656566.9.16.2759", "18937611"]}, {"Citation": "Bonif\u00e1cio M.J., Palma P.N., Almeida L., Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinso\u2019s disease. CNS Drug Rev. 2007;13:352\u2013379. doi: 10.1111/j.1527-3458.2007.00020.x.", "ArticleIdList": ["10.1111/j.1527-3458.2007.00020.x", "PMC6494163", "17894650"]}, {"Citation": "Xu G., Zhang S., Zheng L., Hu Z., Cheng L., Chen L., Li J., Shi Z. In silico identification of A1 agonists and A2a inhibitors in pain based on molecular docking strategies and dynamics simulations. Purinergic Signal. 2021:1\u201311. doi: 10.1007/s11302-021-09808-4.", "ArticleIdList": ["10.1007/s11302-021-09808-4", "34677752"]}, {"Citation": "Rohilla S., Bansal R., Chauhan P., Kachler S., Klotz K.-N. A New Series of 1, 3-Dimethylxanthine Based Adenosine A2A Receptor Antagonists as a Non-Dopaminergic Treatment of Parkinson\u2019s Disease. Curr. Drug Discov. Technol. 2021;18:7\u201317. doi: 10.2174/1570163817666200827112252.", "ArticleIdList": ["10.2174/1570163817666200827112252", "32860362"]}, {"Citation": "G\u00f3mez-Benito M., Granado N., Garc\u00eda-Sanz P., Michel A., Dumoulin M., Moratalla R. Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front. Pharmacol. 2020;11:356. doi: 10.3389/fphar.2020.00356.", "ArticleIdList": ["10.3389/fphar.2020.00356", "PMC7191035", "32390826"]}, {"Citation": "Kumar R., Bavi R., Jo M.G., Arulalapperumal V., Baek A., Rampogu S., Kim M.O., Lee K.W. New compounds identified through in silico approaches reduce the \u03b1-synuclein expression by inhibiting prolyl oligopeptidase in vitro. Sci. Rep. 2017;7:10827. doi: 10.1038/s41598-017-11302-0.", "ArticleIdList": ["10.1038/s41598-017-11302-0", "PMC5589771", "28883518"]}, {"Citation": "Kozio\u0142 E., Luca S.V., A\u011falar H.G., Sa\u011fl\u0131k B.N., Demirci F., Marcourt L., Wolfender J.-L., J\u00f3\u017awiak K., Skalicka-Wo\u017aniak K. Rutamarin: Efficient Liquid\u2013Liquid Chromatographic Isolation from Ruta graveolens L. and Evaluation of Its In vitro and in silico MAO-B Inhibitory Activity. Molecules. 2020;25:2678. doi: 10.3390/molecules25112678.", "ArticleIdList": ["10.3390/molecules25112678", "PMC7321355", "32527030"]}, {"Citation": "Nam M.-H., Park M., Park H., Kim Y., Yoon S., Sawant V.S., Choi J.W., Park J.-H., Park K.D., Min S.-J. Indole-substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson\u2019s disease. ACS Chem. Neurosci. 2017;8:1519\u20131529. doi: 10.1021/acschemneuro.7b00050.", "ArticleIdList": ["10.1021/acschemneuro.7b00050", "28332824"]}, {"Citation": "Za\u0142uski M., Schabikowski J., Schlenk M., Olejarz-Maciej A., Kubas B., Karcz T., Kuder K., Latacz G., Zygmunt M., Synak D. Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies. Bioorg. Med. Chem. 2019;27:1195\u20131210. doi: 10.1016/j.bmc.2019.02.004.", "ArticleIdList": ["10.1016/j.bmc.2019.02.004", "30808606"]}, {"Citation": "Cuy\u00e0s E., Verdura S., Lozano-S\u00e1nchez J., Viciano I., Llorach-Par\u00e9s L., Nonell-Canals A., Bosch-Barrera J., Brunet J., Segura-Carretero A., Sanchez-Martinez M. The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. Food Chem. Toxicol. 2019;128:35\u201345. doi: 10.1016/j.fct.2019.03.049.", "ArticleIdList": ["10.1016/j.fct.2019.03.049", "30935952"]}, {"Citation": "Govindasamy H., Magudeeswaran S., Poomani K. Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics/molecular mechanics and molecular dynamics simulations. J. Biomol. Struct. Dyn. 2020;38:5307\u20135319. doi: 10.1080/07391102.2019.1699446.", "ArticleIdList": ["10.1080/07391102.2019.1699446", "31779524"]}, {"Citation": "Patel C.N., Georrge J.J., Modi K.M., Narechania M.B., Patel D.P., Gonzalez F.J., Pandya H.A. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer\u2019s disease. J. Biomol. Struct. Dyn. 2018;36:3938\u20133957. doi: 10.1080/07391102.2017.1404931.", "ArticleIdList": ["10.1080/07391102.2017.1404931", "PMC6371058", "29281938"]}, {"Citation": "National Center for Biotechnology Information  PubChem Compound Summary for CID 100633, Karanjin.  [(accessed on 17 February 2021)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/Karanjin."}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997;23:3\u201325. doi: 10.1016/S0169-409X(96)00423-1.", "ArticleIdList": ["10.1016/S0169-409X(96)00423-1", "11259830"]}, {"Citation": "Zhang M.-Q., Wilkinson B. Drug discovery beyond the \u2018rule-of-five\u2019. Curr. Opin. Biotechnol. 2007;18:478\u2013488. doi: 10.1016/j.copbio.2007.10.005.", "ArticleIdList": ["10.1016/j.copbio.2007.10.005", "18035532"]}, {"Citation": "Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein Data Bank. Nucleic Acids Res. 2000;28:235\u2013242. doi: 10.1093/nar/28.1.235.", "ArticleIdList": ["10.1093/nar/28.1.235", "PMC102472", "10592235"]}, {"Citation": "Swain S.S., Paidesetty S.K., Dehury B., Sahoo J., Vedithi S.C., Mahapatra N., Hussain T., Padhy R.N. Molecular docking and simulation study for synthesis of alternative dapsone derivative as a newer antileprosy drug in multidrug therapy. J. Cell. Biochem. 2018;119:9838\u20139852. doi: 10.1002/jcb.27304.", "ArticleIdList": ["10.1002/jcb.27304", "30125973"]}, {"Citation": "Swain S.S., Paidesetty S.K., Padhy R.N. Synthesis of novel thymol derivatives against MRSA and ESBL producing pathogenic bacteria. Nat. Prod. Res. 2019;33:3181\u20133189. doi: 10.1080/14786419.2018.1474465.", "ArticleIdList": ["10.1080/14786419.2018.1474465", "29792335"]}, {"Citation": "Li X., Buxbaum J.N. Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer\u2019s disease? Mol. Neurodegener. 2011;6:79. doi: 10.1186/1750-1326-6-79.", "ArticleIdList": ["10.1186/1750-1326-6-79", "PMC3267701", "22112803"]}, {"Citation": "Fridman C., Greg\u00f3rio S.P., Dias Neto E., Ojopi \u00c9.P.B. Altera\u00e7\u00f5es gen\u00e9ticas na doen\u00e7a de Alzheimer. Arch. Clin. Psychiatry (S\u00e3o Paulo) 2004;31:19\u201325. doi: 10.1590/S0101-60832004000100004.", "ArticleIdList": ["10.1590/S0101-60832004000100004"]}, {"Citation": "Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 2014;6:89. doi: 10.1186/s13195-014-0089-7.", "ArticleIdList": ["10.1186/s13195-014-0089-7", "PMC4304279", "25621019"]}, {"Citation": "Koelsch G. BACE1 function and inhibition: Implications of intervention in the amyloid pathway of Alzheimer\u2019s disease pathology. Molecules. 2017;22:1723. doi: 10.3390/molecules22101723.", "ArticleIdList": ["10.3390/molecules22101723", "PMC6151801", "29027981"]}, {"Citation": "Ridler C. BACE1 inhibitors block new A\u03b2 plaque formation. Nat. Rev. Neurol. 2018;14:126. doi: 10.1038/nrneurol.2018.12.", "ArticleIdList": ["10.1038/nrneurol.2018.12", "29391586"]}, {"Citation": "Bao J., Qin M., Mahaman Y.A.R., Zhang B., Huang F., Zeng K., Xia Y., Ke D., Wang Q., Liu R. BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer\u2019s disease. Proc. Natl. Acad. Sci. USA. 2018;115:3954\u20133959. doi: 10.1073/pnas.1800498115.", "ArticleIdList": ["10.1073/pnas.1800498115", "PMC5899489", "29581300"]}, {"Citation": "Eldar-Finkelman H., Martinez A. GSK-3 inhibitors: Preclinical and clinical focus on CNS. Front. Mol. Neurosci. 2011;4:32. doi: 10.3389/fnmol.2011.00032.", "ArticleIdList": ["10.3389/fnmol.2011.00032", "PMC3204427", "22065134"]}, {"Citation": "Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Rades\u00e4ter A.-C., Jerning E., Markgren P.-O., Borgeg\u00e5rd T. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 2003;278:45937\u201345945. doi: 10.1074/jbc.M306268200.", "ArticleIdList": ["10.1074/jbc.M306268200", "12928438"]}, {"Citation": "Wang W., Li M., Wang Y., Li Q., Deng G., Wan J., Yang Q., Chen Q., Wang J. GSK-3\u03b2 inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/\u03b2-catenin signaling pathway after acute ischemic stroke in rats. Mol. Neurobiol. 2016;53:7028\u20137036. doi: 10.1007/s12035-015-9607-2.", "ArticleIdList": ["10.1007/s12035-015-9607-2", "PMC4909586", "26671619"]}, {"Citation": "Kremer A., Louis J.V., Jaworski T., Van Leuven F. GSK3 and Alzheimer\u2019s disease: Facts and fiction. Front. Mol. Neurosci. 2011;4:17. doi: 10.3389/fnmol.2011.00017.", "ArticleIdList": ["10.3389/fnmol.2011.00017", "PMC3162188", "21904524"]}, {"Citation": "Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 1997;56:321\u2013339. doi: 10.1097/00005072-199704000-00001.", "ArticleIdList": ["10.1097/00005072-199704000-00001", "9100663"]}, {"Citation": "Zhou R., Bickler P. Interaction of isoflurane, tumor necrosis factor-\u03b1 and \u03b2-amyloid on long-term potentiation in rat hippocampal slices. Anesth. Analg. 2017;124:582\u2013587. doi: 10.1213/ANE.0000000000001698.", "ArticleIdList": ["10.1213/ANE.0000000000001698", "28099324"]}, {"Citation": "Rees T.M., Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer\u2019s disease. Drugs Today. 2003;39:75\u201383. doi: 10.1358/dot.2003.39.1.740206.", "ArticleIdList": ["10.1358/dot.2003.39.1.740206", "12669110"]}, {"Citation": "Wilson C.N., Mustafa S.J. Adenosine Receptors in Health and Disease. Springer; Cham, Switzerland: 2009."}, {"Citation": "Olanow C.W., Brundin P. Parkinson\u2019s disease and alpha synuclein: Is Parkinson\u2019s disease a prion-like disorder? Mov. Disord. 2013;28:31\u201340. doi: 10.1002/mds.25373.", "ArticleIdList": ["10.1002/mds.25373", "23390095"]}, {"Citation": "Mart\u00ednez-Jauand M., Sitges C., Rodriguez V., Picornell A., Ramon M., Buskila D., Montoya P. Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur. J. Pain. 2013;17:16\u201327. doi: 10.1002/j.1532-2149.2012.00153.x.", "ArticleIdList": ["10.1002/j.1532-2149.2012.00153.x", "22528689"]}, {"Citation": "Teo K.C., Ho S.-L. Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson\u2019s disease. Transl. Neurodegener. 2013;2:19. doi: 10.1186/2047-9158-2-19.", "ArticleIdList": ["10.1186/2047-9158-2-19", "PMC3847108", "24011391"]}, {"Citation": "Choi J.W., Jang B.K., Cho N.-C., Park J.-H., Yeon S.K., Ju E.J., Lee Y.S., Han G., Pae A.N., Kim D.J. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg. Med. Chem. 2015;23:6486\u20136496. doi: 10.1016/j.bmc.2015.08.012.", "ArticleIdList": ["10.1016/j.bmc.2015.08.012", "26337020"]}, {"Citation": "Swain S.S., Singh S.R., Sahoo A., Panda P.K., Hussain T., Pati S. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro. Proteins. 2022 doi: 10.1002/prot.26341.", "ArticleIdList": ["10.1002/prot.26341", "PMC9111047", "35384056"]}, {"Citation": "Al-Wahaibi1 L.H., Joubert J., Blacque O., Al-Shaalan N.H., El-Emam A.A. Crystal structure, Hirshfeld surface analysis and DFT studies of 5-(adamantan-1-yl)-3-[(4-chlorobenzyl)sulfanyl]-4-methyl-4H-1,2,4-triazole, a potential 11\u03b2HSD1 inhibitor. Sci. Rep. 2019;9:19745. doi: 10.1038/s41598-019-56331-z.", "ArticleIdList": ["10.1038/s41598-019-56331-z", "PMC6930263", "31875009"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "3", "Day": "9"}, {"Year": "2022", "Month": "4", "Day": "21"}, {"Year": "2022", "Month": "4", "Day": "25"}, {"Year": "2022", "Month": "5", "Day": "14", "Hour": "1", "Minute": "23"}, {"Year": "2022", "Month": "5", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "29"}], "PublicationStatus": "epublish", "ArticleIdList": ["35566187", "PMC9100660", "10.3390/molecules27092834", "molecules27092834"]}}], "PubmedBookArticle": []}